Emrelis™ (telisotuzumab vedotin-tllv) – New drug approval
May 14, 2025 - AbbVie announced the FDA approval of Emrelis (telisotuzumab vedotin-tllv), for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (≥ 50% of tumor cells with strong [3+] staining), as determined by an FDA-approved test, who have received a prior systemic therapy.
Top